Recently, targeting multiple modes of PI3K and its compensatory pathways like KRAS and YAP/YEAD has been suggested to benefit KRAS-driven tumors [98], but further investigation is needed in gynecological cancers. The gene discussed is PIK3CA; the disease is female reproductive organ cancer.